National Institute for Health and Care Excellence

Single Technology Appraisal (STA)

Palbociclib in combination with fulvestrant for treating advanced, hormone-receptor positive, HER2-negative breast cancer after endocrine therapy [ID3779]

Response to consultee and commentator comments on the draft remit and draft scope (pre-referral)

Please note: Comments received in the course of consultations carried out by NICE are published in the interests of openness and transparency, and to promote understanding of how recommendations are developed. The comments are published as a record of the submissions that NICE has received, and are not endorsed by NICE, its officers or advisory committees.

Comment 1: the draft remit

Section	Consultee/ Commentator	Comments [sic]	Action
Wording	Pfizer Ltd	The wording is appropriate.	Comment noted. No changes to the scope required
Timing Issues	Pfizer Ltd	The timing of the appraisal is appropriate	Comment noted. No changes to the scope required
Additional comments on the draft remit	Pfizer Ltd	N/A	Noted.

Comment 2: the draft scope

Section	Consultee/ Commentator	Comments [sic]	Action
Background information	Pfizer Ltd	The information is appropriate.	Comment noted. No changes to the scope are needed.
The technology/ intervention	Pfizer Ltd	The description is accurate.	Comments noted. The technology/intervention has been amended.
Population	Pfizer Ltd	The wording in the draft scope is appropriate: “People with hormone receptor-positive HER2-negative, locally advanced or metastatic breast cancer who have had prior endocrine therapy”.	Comment noted. No changes to the scope are needed.
Comparators	Pfizer Ltd	Due to changes in clinical practice during the period palbociclib has been in the Cancer Drugs Fund (CDF), it was agreed that this CDF exit appraisal should be re-scoped to reflect the comparators currently used in the NHS. Everolimus plus exemestane is used in a small number of patients in this 2nd-line setting and is no longer a relevant comparator given the recent NICE technology appraisals 687 and 725 which recommended abemaciclib with fulvestrant and ribociclib with fulvestrant for treating hormone receptor-positive, HER2-negative, advanced breast cancer in people who have had previous endocrine therapy. Ribociclib with fulvestrant and abemaciclib with fulvestrant are the key comparators for palbociclib in this population.	Thank you for your comment. As exemestane plus everolimus is used in clinical practice in the NHS, it is a relevant comparator and is included in the scope.
Outcomes	Pfizer Ltd	No comments.	Noted.

Section	Consultee/ Commentator	Comments [sic]	Action
Economic analysis	Pfizer Ltd	We intend to submit a cost-minimisation analysis versus the CDK4/6 inhibitors (abemaciclib and ribociclib) in combination with fulvestrant.	Comment noted. No changes to the scope are needed.
Equality and Diversity	Pfizer Ltd	No comments	Noted.
Other considerations	Pfizer Ltd	No comments	Noted.
Innovation	Pfizer Ltd	No comments	Noted.
Questions for consultation	Pfizer Ltd	No comments	Noted
Additional comments on the draft scope	Pfizer Ltd	No comments	Noted.

The following consultees/commentators indicated that they had no comments on the draft remit and/or the draft scope:

None